Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wet AMD AND Age-Related Macular Degeneration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Wet AMD AND Age-Related Macular Degeneration. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2013-004464-54 Sponsor Protocol Number: BAY86-5321/16995 Start Date*: 2014-05-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic ...
    Medical condition: Polypoidal Choroidal Vasculopathy (PCV)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002821-31 Sponsor Protocol Number: AKST4290-206 Start Date*: 2019-10-10
    Sponsor Name:Alkahest, Inc
    Full Title: The Effect of AKST4290 on Choroidal Blood Flow in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003229-17 Sponsor Protocol Number: Protocol1 Start Date*: 2014-10-06
    Sponsor Name:Inst of OPhthalmology, Lund University
    Full Title: To compare the effect of Eylea given every other month after three injections to treatment with a gradual extension intervals. and examine retinal function with electroretinography (ERG) in patient...
    Medical condition: To evaluate if Aflibercept given every eighth week from start after an initial loading dose in age-related macular degeneration (AMD), is as effective as dosing as "Treat and extend" where treati...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000225-27 Sponsor Protocol Number: KS301P107 Start Date*: 2021-10-26
    Sponsor Name:Kodiak Sciences Inc.
    Full Title: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal A...
    Medical condition: Neovascular (Wet) Age-related Macular Degeneration (wAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    20.0 10015919 - Eye disorders 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004838-41 Sponsor Protocol Number: CSOK583A12301 Start Date*: 2021-03-04
    Sponsor Name:Hexal AG
    Full Title: A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascula...
    Medical condition: The ‘wet’ form of age-related macular degeneration (AMD) is a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) LV (Completed) FR (Completed) SK (Completed) BG (Completed) HU (Completed) PT (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-004409-42 Sponsor Protocol Number: LRP/LUBT010/2016/008 Start Date*: 2020-11-23
    Sponsor Name:Lupin Limited (Biotechnology Division)
    Full Title: A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Neovascular Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-003133-42 Sponsor Protocol Number: 1672_2019 Start Date*: 2020-02-14
    Sponsor Name:Medical University of Vienna, Department of Ophthalmology and Optometry
    Full Title: Personalized treatment aided by automated analysis of fluid in active neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study
    Medical condition: Nevoascular age related macular degneration (nAMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003923-39 Sponsor Protocol Number: FYB203-03-01 Start Date*: 2020-03-18
    Sponsor Name:Bioeq GmbH
    Full Title: A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age Rela...
    Medical condition: Neovascular Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004917-10 Sponsor Protocol Number: TIGER Start Date*: 2023-06-29
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-gro...
    Medical condition: Submacular haemorrhage secondary to exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075718 Exudative age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004132-37 Sponsor Protocol Number: SCD411-CP101 Start Date*: 2020-07-22
    Sponsor Name:SamChunDang Pharm. Co. Ltd.
    Full Title: A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity between SCD411 and Eylea® in Subjects wi...
    Medical condition: Neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000716-28 Sponsor Protocol Number: CRTH258A2303 Start Date*: 2019-09-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in pa...
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IT (Completed) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001970-41 Sponsor Protocol Number: 0504-19 Start Date*: 2022-03-18
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular De...
    Medical condition: Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002977-33 Sponsor Protocol Number: Luc01AKSI Start Date*: 2006-06-22
    Sponsor Name:University Eye Hospital
    Full Title: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to ag...
    Medical condition: Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to A...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002349-40 Sponsor Protocol Number: CRTH258A2303E1 Start Date*: 2020-11-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for ...
    Medical condition: neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PT (Completed) CZ (Completed) SE (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003651-42 Sponsor Protocol Number: AVT06-GL-C01 Start Date*: 2022-04-14
    Sponsor Name:Alvotech Swiss AG
    Full Title: A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age related Macular D...
    Medical condition: Neovascular (wet) Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) SK (Completed) CZ (Completed) HU (Completed) BG (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001213-36 Sponsor Protocol Number: ISTH-02-211 Start Date*: 2021-06-20
    Sponsor Name:Isarna Therapeutics GmbH
    Full Title: TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The “BETTER” Study
    Medical condition: Neovascular age-related macular degeneration (nAMD) Diabetic Macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001221-40 Sponsor Protocol Number: 1336-0007 Start Date*: 2019-05-06
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Safety, tolerability and pharmacodynamics of single rising intravitreal and multiple rising intravitreal doses of BI 836880 in patients with wAMD (open label, non-randomized, uncontrolled).
    Medical condition: wet age-related macular degeneration (wAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    20.0 10015919 - Eye disorders 10075568 Wet age-related macular degeneration LLT
    20.0 10015919 - Eye disorders 10075718 Exudative age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004145-33 Sponsor Protocol Number: CRTH258AFR03 Start Date*: 2020-04-07
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macul...
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004486-13 Sponsor Protocol Number: QL1205-002 Start Date*: 2019-04-18
    Sponsor Name:Qilu Pharmaceutical Co., Ltd.
    Full Title: A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration
    Medical condition: Subjects With Wet (neovascular) Age-related Macular Degeneration (wAMD), aged ≥50 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) LV (Completed) PL (Completed) BG (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:21:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA